已收盤 07-18 16:00:00 美东时间
-1.300
-1.31%
Integer Holdings (NYSE:ITGR) is gearing up to announce its quarterly earnings o...
04-24 01:01
每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。
04-18 08:48
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119548656129204224.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Keybanc:维持Absci(ABSI)"超配"评级,目标价从5美元升至9美元</p> <p>• Keybanc:维持AbCellera Biologics(ABCL)"超配"评级,目标价从4美元升至5美元</p> <
04-17 08:46
In the preceding three months, 7 analysts have released ratings for Glaukos (NY...
04-17 06:01
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1119185980869894144.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Canaccord Genuity:维持Verve Therapeutics(VERV)"买入"评级,目标价从32美元升至39美元</p> <p>• HC Wainwright & Co.:维持Verve Ther
04-16 09:45
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1117736711687032832.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 杰富瑞:上调内克塔治疗(NKTR)评级至"买入",目标价从1美元升至2美元</p> <p>• Roth MKM:维持Lovesac Co.(LOVE)"买入"评级,目标价从22美元升至28美元</p> <p>• Macq
04-14 07:05
Glaukos Corp : Citigroup Cuts Target Price to $140 From $164
04-07 19:18
All three major U.S. stock indices are down Friday as traders reacted to several sets of fresh data that raised concerns about the economic outlook.
02-22 02:01
Glaukos shares are trading lower after the company reported Q4 Adj Eps miss.
02-21 21:18
Baxter International exceeded Q4 earnings and revenue estimates, with strong pharmaceutical sales. The company issued a mixed 2025 outlook amid cost pressures.
02-21 01:41